Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2026 16:05 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...
January 06, 2026 08:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the...
November 10, 2025 16:05 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated...